Table 1 Summary of characteristics of the tumor B-Cell lines involved in this study
From: Synthetic Phosphoantigens Enhance Human Vγ9Vδ2 T Lymphocytes Killing of Non-Hodgkin’s B Lymphoma
Maturation Stage | Cell Lines | Main Cytogenetic Abnormalities | EBV Status | Description | Reference |
|---|---|---|---|---|---|
pre-GC | REC1 | t(11;14) | − | Mantle cell NHL | (87) |
OCI-Ly8 | t(14;18) | − | DLC (CB/LB) NHL | (88) | |
DEAU | − | DLC (CB) NHL | (89) | ||
VAL | t(8;14;18) & t(3;4) | − | DLC (CB) NHL | (90) | |
LIB | − | DLC (IB) NHL | * | ||
HLY-1 | t(3;5) | − | (IB) NHL | (91) | |
GC | RL | t(14;18) | − | DLC NHL | (92) |
/ | MIEUL | − | Burkitt’s like NHL | * | |
post-GC | DAUDI | t(8;14) | + | Burkitt’s NHL | ATCC#CCL-213 |
RAJI | t(8;14) | + | Burkitt’s NHL | ATCC#CCL-86 | |
Gift from G. | |||||
BL9 | + | Burkitt’s NHL | Lenoir, UCB, Lyon, France | ||
DG75 | t(8;14) | − | Burkitt’s NHL | (93) | |
PASC | t(8;14) | − | Burkitt’s NHL | * | |
L-428 | − | Hodgkin’s disease derived B cell, IgS− | (94) | ||
post-GC | NCI-H 929 | − | Plasmocytoma, IgA-producing | ATCC#CRL-9068 | |
RPMI 8226 | − | Plasmocytoma, λ light chain-secreting | ATCC#CCL-155 | ||
(non-B) | K562 | − | Chronic myelogenous leukemia | ATCC#CCL-243 | |
(non-B) | JURKAT | − | T-lymphoblastic lymphoma/leukemia | ATCC#CRL-8163 |